Investigational drug · Phase 2
ATX101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Total Knee Arthroplasty (Postoperative Pain).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
31
Any phase or sponsor naming "ATX101"
First trial start
2025
Feb 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATX101", any sponsor or status.
- Phase 112
Conditions studied
As listed on its trial records.
- Total Knee Arthroplasty (Postoperative Pain)
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "ATX101" as an intervention, largest first.
Kythera BiopharmaceuticalsIndustry
NCT02438813 · 1,029 participants · Start May 11, 2015 · Primary completion Nov 10, 2016
Drug: Deoxycholic acid · For: Submental Fullness
Sites: Tucson, Arizona; Beverly Hills, California; Calabasas, California · 95 sites in all
- Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01546142 · 516 participants · Start Mar 2012 · Primary completion May 2013
Drug: Deoxycholic acid injection; Placebo · For: Moderate or Severe Submental Fullness
Sites: Little Rock, Arkansas; Beverly Hills, California; Los Angeles, California · 35 sites in all
- Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01542034 · 506 participants · Start Feb 2012 · Primary completion May 2013
Drug: Deoxycholic acid injection; Placebo · For: Moderate or Severe Submental Fullness
Sites: Birmingham, Alabama; Beverly Hills, California; Irvine, California · 36 sites in all
- Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental FatPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01305577 · 363 participants · Start Dec 2010 · Primary completion Jan 2012
Drug: Deoxycholic acid injection; Placebo · For: Moderate or Severe Submental Fullness
Sites: Oudenaarde, Belgium; Arras, France; Cannes, France · 30 sites in all
- Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental FatPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01294644 · 360 participants · Start Jan 2011 · Primary completion Feb 2012
Drug: Deoxycholic acid injection; Placebo · For: Moderate or Severe Submental Fullness
Sites: Geel, Belgium; Genk, Belgium; Besançon, France · 29 sites in all
- Phase 2B Study Assessing Pain Relief After Replacement of the KneePivotal-lookingCompleted
Allay Therapeutics, Inc.Industry
NCT06799845 · 226 participants · Start Feb 3, 2025 · Primary completion Oct 3, 2025
Drug: ATX101; bupivacaine hydrochloride and 1 more · For: Total Knee Arthroplasty (Postoperative Pain)
Sites: Little Rock, Arkansas; Tamarac, Florida; Atlanta, Georgia · 11 sites in all
- Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101Pivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT02163902 · 224 participants · Start Dec 2013 · Primary completion Jan 2016
Drug: ATX-101; Placebo · For: Submental Fat; Healthy
Sites: San Diego, California; Englewood, Colorado; Coral Gables, Florida · 15 sites in all
- Evaluation of the Effect of ATX-101 on QT/QTc IntervalsPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01706679 · 218 participants · Start Oct 2012 · Primary completion Feb 2013
Drug: ATX-101 (10 mg/ml); ATX-101 (20 mg/ml) and 2 more · For: Healthy
Sites: Miramar, Florida
Kythera BiopharmaceuticalsIndustry
NCT02159729 · 205 participants · Start Feb 2009 · Primary completion Dec 2015
Drug: Placebo; ATX-101 (1 mg/cm^2) and 2 more · For: Submental Fat; Healthy
Sites: Birmingham, Alabama; Beverly Hills, California; San Francisco, California · 20 sites in all
AllerganAbbVie (ABBV)
NCT03682471 · 201 participants · Start Feb 14, 2012 · Primary completion Dec 13, 2013
Drug: Deoxycholic acid Injection; Placebo · For: Subcutaneous Fat
Sites: Augsburg, Germany; Berlin, Germany; Bochum, Germany · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Bioconversion of cholic acid into deoxycholic acid by a multi-enzyme catalytic system.
Ma X, Du Z, Zhang T, et al. · Bioorg Chem 2026
- Nonsurgical Management of Submental Fullness for Double Chin Reduction: A Systematic Review.
Zahedi K, Gheisari M · J Cosmet Dermatol 2026
- Targeting the master of the replication fork-PCNA.
Gong Y, Hu W, Li M · Pathol Res Pract 2026
- A Prospective, Open-Label Study to Evaluate Dual-Modality Treatment With Deoxycholic Acid (ATX-101) and Hyaluronic Acid (VYC-20L) for Overall Improvement in Jawline Contour.
Goodman GJ, Roberts S, Cook N, et al. · Aesthet Surg J Open Forum 2025
- Targeting the "Undruggable": Small-Molecule Inhibitors of Proliferating Cell Nuclear Antigen (PCNA) in the Spotlight in Cancer Therapy.
Wang T, Wang Z · J Med Chem 2025
- Peripheral Nerve Injury After Deoxycholic Acid (ATX-101) Injection in an Experimental Rat Model.
Chi D, Pinni S, Maloy S, et al. · Aesthet Surg J 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.